Immunovia AB (Publ) nomination committee appointed for AGM 2018
According to the instruction that was adopted at the Immunovia AB (Publ) AGM April 25 2017, the nomination committee should consist of three members.
LUND, Sweden ― The chairman of the board shall contact the by votes largest registered owner or otherwise known shareholder per September 1, 2017 and request the same to appoint three members to the nomination committee. The by votes largest shareholder’s suggestion for a new nomination committee shall thereafter be anchored among the by votes second and third largest registered owners or otherwise known shareholders per September 1, 2017.
Based on the above, the nomination committee have for the 2018 AGM been determined to consist of the following persons whom together represent approximately 20 percent of the number of shares and votes in the Company per September 1 2017:
- Sara Ek, representing Sara Ek, Chairman of the Nomination Committee
- Carl Borrebaeck representing Carl Borrebaeck, Chairman of the Board; and
- Astrid Samuelsson, representing Handelsbanken
The suggestion from the nomination committee will be presented in the notice to the AGM 2018 as well as on the Company website, www.immunovia.com.
Shareholders who wish to leave suggestions to the nomination committee are welcome to contact the nomination committee at the Company address. In order for the nomination committee to take a suggestion into account, the suggestion must have been received in a timely manner before the AGM, January 31 at the latest.
For more information, please contact:
Mats Grahn
Chief Executive Officer, CEO, Immunovia
Tel.: +46-70-5320230
Email: mats.grahn@immunovia.com
About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above.
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.